Veritas Pharma Inc (VRT.CN) WACC Analysis

As of May 29, 2025, Veritas Pharma Inc (VRT.CN) carries a Weighted Average Cost of Capital (WACC) of 7.8%. WACC reflects the blended rate Veritas Pharma Inc must pay to both equity and debt holders.

Within that, the cost of equity is 6.6%, the cost of debt is 5.0%, and the effective tax rate is 26.5%.

Breakdown of WACC Components

• Long-term bond rate: 3.4% – 3.9%
• Equity market risk premium: 4.7% – 5.7%
• Adjusted beta: 0.69 – 0.84
• Additional risk adjustment: 0.0% – 0.5%
• Debt-to-equity ratio: 0.03

What It Means for Investors

With a selected WACC of 7.8%, Veritas Pharma Inc must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects an attractive low cost of capital.